Showing posts with label syndrome. Show all posts
Showing posts with label syndrome. Show all posts

Thursday, 15 August 2013

New Mums with Polycystic Ovary Syndrome - substantial link between high BMI's and low breastfeeding rates

Main Category: Women's Health / Gynecology
Also Included In: Endocrinology;  Obesity / Weight Loss / Fitness;  Pregnancy / Obstetrics
Article Date: 14 Aug 2013 - 2:00 PDT Current ratings for:
New Mums with Polycystic Ovary Syndrome - substantial link between high BMI's and low breastfeeding rates
5 starsnot yet rated

New Mums with Polycystic Ovary Syndrome (PCOS) are more likely to be overweight and less likely to breastfeed than their counterparts in the healthy weight range, say scientists.

Already known to affect 1 in 5 Australian women, approximately one million women of childbearing age, PCOS is a growing concern and scientists are calling for further research into the clinical features including fertility issues associated with the condition.

PCOS is still one of the country's most underdiagnosed conditions and is well-known for being linked to other health issues such as a high BMI, Type II Diabetes and infertility.

A new study conducted by scientists at Monash University investigating the link between breastfeeding habits and body mass index in women with and without PCOS has found a substantial link between high BMI's and low breastfeeding rates.

Professor Helena Teede, Natalie Nanayakkara, Dr Anju Joham, Dr Sophia Zoungas, Associate Professor Deborah Loxton and Professor Eszter Vanky undertook the study using data from the Australian Longitudinal Women's Health Study.

Working at the School of Public Health and Preventive Medicine, they aimed to ascertain the link between breastfeeding, PCOS and pregnant women who are overweight or obese.

The findings are just one of the many research abstracts to be discussed at the Annual Scientific Meeting of the Endocrine Society of Australia and the Society for Reproductive Biology 2013, from August 25-28 at the Sydney Convention and Exhibition Centre.

Professor Helena Teede said research into PCOS is much needed. "There is a widespread under-diagnosis of this condition and symptoms are often overlooked by health practitioners up until a woman has difficulty conceiving," said Professor Teede.

"Recent figures show that approximately 72 per cent of women diagnosed with PCOS require costly fertility assistance, but when provided with this assistance, family sizes are similar to women without PCOS - " These startling new figures prompted us to conduct research into reproductive issues associated with the condition," she said.

The researchers conducted a cross-sectional analysis of very large community based dataset from the government-funded, Australian Longitudinal Study on Women's Health. Participants were women aged 31 to 36 years old, and were randomly selected from the Medicare database.

"There is significant existing evidence that women who suffer from PCOS are more likely to be overweight. Small studies also suggested that women with PCOS had lower breastfeeding rates.

"Breast feeding is important in limiting weight retention after pregnancy in new mothers. With this study, we wanted to find whether there was a further link between PCOS and breastfeeding behaviours.

"The study discovered that, while there was no definitive link between PCOS and breastfeeding, there was a strong link between weight and breast feeding and for every five unit increase in BMI there was an approximate 20 day reduction in breastfeeding duration.

"What we want to see happening as a result of this study is increased lactation support for women who are overweight," she said.

Obesity is a growing concern in Australia with recent ABS statistics showing 62.8 per cent of all Australians fall in the overweight or obese categories, defined by a minimum BMI rating of 25.

"Ultimately, rising obesity rates are now the primary cause of chronic disease in Australia and are at the root of some of our growing health issues including PCOS. As a nation we are leading increasingly sedentary lives, which serves to further compound the issue," said Professor Teede.

"On average, women gain 700g per year but recent research has shown that women diagnosed with PCOS gain almost three times that amount.

"The figures are eye-opening and further highlight the need for more study in the area to help provide greater support to women affected by PCOS.

"By addressing things such as breastfeeding habits of women with PCOS we can better understand how to tackle the growing public health issue of the condition," she said.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our women's health / gynecology section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

The Endocrine Society of Australia. "New Mums with Polycystic Ovary Syndrome - substantial link between high BMI's and low breastfeeding rates." Medical News Today. MediLexicon, Intl., 14 Aug. 2013. Web.
14 Aug. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'New Mums with Polycystic Ovary Syndrome - substantial link between high BMI's and low breastfeeding rates'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Thursday, 1 August 2013

Cholesterol connection to Rett Syndrome

Featured Article
Academic Journal
Main Category: Neurology / Neuroscience
Also Included In: Genetics;  Pediatrics / Children's Health;  Autism
Article Date: 31 Jul 2013 - 3:00 PDT Current ratings for:
Cholesterol connection to Rett Syndrome
not yet rated5 stars

Statins, a class of cholesterol-lowering drugs found in millions of medicine cabinets, may hold the key to finding a treatment for Rett Syndrome, a severe autistic disorder that affects young girls.

The Connecticut-based Rett Syndrome Research Trust (RSRT) has sponsored work to identify a number of targetable genes that act on the Rett gene, MECP2 (methyl-CpG-binding protein 2), in mice. Results of the cholesterol metabolism in Rett syndrome study are published in the journal Nature Genetics.

MECP2 turns other genes on or off by disrupting chromatin, the DNA-protein mix that makes up chromosomes. This was well known to be linked to Rett Syndome, which affects about one in 10,000 girls in Western countries, causing them to lose speech, mobility and use of their hands while still toddlers.

Many girls also suffer seizures, orthopedic and severe digestive problems, as well as breathing and other autonomic impairments. Most live into adulthood but require round-the-clock care.

The study's senior author Professor Monica Justice - from the departments of molecular and human genetics, and molecular physiology and biophysics at Houston's Baylor College of Medicine - decided to look beyond MECP2, hoping to find new drug targets that might improve symptoms or even reverse the course of the disease.

This does seem possible: in 2007, Prof. Adrian Bird - Buchanan professor of genetics at the Wellcome Trust centre for cell biology at the University of Edinburgh - showed that Rett symptoms in mice were reversible regardless of the age of the animal.

Since then, exploring cholesterol metabolism has become an emerging area in neurological diseases, with statin drugs being tested in fragile X syndrome, neurofibromatosis, amyotrophic lateral sclerosis, and other conditions. But cholesterol had not been on the radar for Rett Syndrome - until now.

Prof. Monica Justice said:

"Our screen was to see if we could suppress the symptoms to reveal alternative pathways to treatment. The cholesterol hit was a big one."

The screen was unbiased - the researchers were looking for any gene that would interact with MECP2 in a useful way, rather than employing a candidate gene approach based on hypotheses.

Prof. Monica Justice and her team injected healthy male mice with a chemical called ENU (a form of nitrosourea) that mutates sperm stem cells randomly, then mated the males to Rett females. The researchers then looked for offspring whose genes made them liable to develop the syndrome but who remained healthy.

The most drug-targetable gene they found was squalene epoxidase (Sqle), which is linked to the cholesterol biosynthetic pathway.

"Frankly, this discovery was a surprise," Prof. Monica Justice said, noting that this enzyme is different from the rate-limiting enzyme (HMG CoA reductase) influenced by statin drugs.

The next step was to test several statins (fluvastatin and lovastatin) on Rett mice. Like the Sqle mutation, the drugs improved symptoms. Treated mice performed well on mobility and gross motor tests, had better overall health scores and lived longer. However, the drugs did not improve breathing.

First author Christie Buchovecky, a Baylor graduate student, said:

"When we saw the mutation in a cholesterol pathway enzyme, we immediately thought of statin drugs.

Now that our eyes have opened to what is going on, we have a multitude of drugs that modulate lipid metabolism that we can try in addition to statins."

With additional RSRT funding, pediatric neurologist and director of the Tri-State Rett Syndrome Center in New York, Dr. Sasha Djukic undertook a detailed review of lipid data in girls with Rett Syndrome.

She has found that some young Rett sufferers have elevated cholesterol levels that normalize as they grow older. These data are not included in the published study but will be part of a subsequent paper, based on clinical trial.

Prof. Monica Justice says a series of carefully designed and rigorously executed clinical trials are essential to determine if the mice results will also apply to girls with Rett Syndrome. These should also determine ways to identify which girls are most likely to respond to statins, which drugs to trial and what dosages are effective without being toxic.

Dr. Sasha Djukic also counsels caution.

"Although statins are blockbuster drugs taken by a large percentage of the population they are not without risks and side-effects, and data on statins in the general pediatric population are quite limited."

"One of the key objectives of the clinical trial will be to determine correct dosages for Rett symptoms," Dr. Sasha Djukic adds. "It's important to note that the mice in Dr. Justice's study received very low doses of statins.

"I urge parents to resist any temptation to medicate their children with off-label statins."

Prof. Monica Justice says the biggest finding from the study is the discovery that the cholesterol pathway is so important to the pathology of Rett Syndrome.

"Emerging evidence from both mice and humans suggest that Rett Syndrome may have a component of disease that is metabolic," Prof. Justice said.

"Certainly, this study will further clarify our data, and may suggest avenues for treatment that were previously unexplored."

Written by Nick Valentine


Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today Visit our neurology / neuroscience section for the latest news on this subject. "A suppressor screen in Mecp2 mutant mice implicates cholesterol metabolism in Rett syndrome," Buchovecky CM, Turley SD, Brown HM et al, Nature Genetics, published online July 28, 2013 DOI 10.1038/ng.2714. Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Valentine, Nick. "Cholesterol connection to Rett Syndrome." Medical News Today. MediLexicon, Intl., 31 Jul. 2013. Web.
1 Aug. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Cholesterol connection to Rett Syndrome'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Tuesday, 30 July 2013

Anti-herpesvirus drug treatment may benefit some chronic fatigue syndrome patients

Main Category: Infectious Diseases / Bacteria / Viruses
Article Date: 30 Jul 2013 - 0:00 PDT Current ratings for:
Anti-herpesvirus drug treatment may benefit some chronic fatigue syndrome patients
not yet ratednot yet rated

Many experts believe that chronic fatigue syndrome (CFS) has several root causes including some viruses. Now, lead scientists Shara Pantry, Maria Medveczky and Peter Medveczky of the University of South Florida's Morsani College of Medicine, along with the help of several collaborating scientists and clinicians, have published an article in the Journal of Medical Virology suggesting that a common virus, Human Herpesvirus 6 (HHV-6), is the possible cause of some CFS cases.

Over 95 percent of the population is infected with HHV-6 by age 3, but in those with normal immune systems the virus remains inactive. HHV-6 causes fever and rash (or roseola) in infants during early childhood, and is spread by saliva. In immunocompromised patients, it can reactivate to cause neurological dysfunction, encephalitis, pneumonia and organ failure.

"The good news reported in our study is that antiviral drugs improve the severe neurological symptoms, including chronic pain and long-term fatigue, suffered by a certain group of patients with CFS," said Medveczky, who is a professor of molecular medicine at USF Health and the study's principal investigator. "An estimated 15,000 to 20,000 patients with this CFS-like disease in the United States alone may ultimately benefit from the application of this research including antiviral drug therapy."

The link between HHV-6 infection and CFS is quite complex. After the first encounter, or "primary infection," all nine known human herpesviruses become silent, or "latent," but may reactivate and cause diseases upon immunosuppression or during aging. A previous study from the Medveczky laboratory showed that HHV-6 is unique among human herpesviruses; during latency, its DNA integrates into the structures at the end of chromosomes known as telomeres.

Furthermore, this integrated HHV-6 genome can be inherited from parent to child, a condition commonly referred to as "chromosomally integrated HHV-6," or CIHHV-6. By contrast, the "latent" genome of all other human herpesviruses converts to a circular form in the nucleus of the cell, not integrated into the chromosomes, and not inheritable by future generations.

Most studies suggest that around 0.8 percent of the U.S. and U.K. population is CIHHV6 positive, thus carrying a copy of HHV-6 in each cell. While most CIHHV-6 individuals appear healthy, they may be less able to defend themselves against other strains of HHV-6 that they might encounter. Medveczky reports that some of these individuals suffer from a CFS-like illness. In a cohort of CFS patients with serious neurological symptoms, the researchers found that the prevalence of CIHHV-6 was over 2 percent, or more than twice the level found in the general public. In light of this finding, the authors of the study suggest naming this sub-category of CFS "Inherited Human Herpesvirus 6 Syndrome," or IHS.

Medveczky's team discovered that untreated CIHHV-6 patients with CFS showed signs that the HHV-6 virus was actively replicating: determined by the presence of HHV-6 messenger RNA (mRNA), a substance produced only when the virus is active. The team followed these patients during treatment, and discovered that the HHV-6 mRNA disappeared by the sixth week of antiviral therapy with valganciclovir, a drug used to treat closely related cytomegalovirus (HHV-5). Of note, the group also found that short-term treatment regimens, even up to three weeks, had little or no impact on the HHV-6 mRNA level.

The investigators assumed that the integrated virus had become reactivated in these patients; however, to their surprise, they found that these IHS patients were infected by a second unrelated strain of HHV-6.

Further studies are needed to confirm that immune dysregulation, along with subsequent chronic persistence of the HHV-6 virus, is the root cause of the IHS patients' clinical symptoms, the researchers report.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our infectious diseases / bacteria / viruses section for the latest news on this subject.

The USF-led study was supported by the HHV-6 Foundation and the National Institutes of Health.

Article citation: “Persistent human herpesvirus-6 infection in patients with an inherited form of the virus; ” Shara N. Pantry, Maria M. Medveczky, Jesse H. Arbuckle, Janos Luka,Jose G. Montoya, Jianhong Hu, Rolf Renne, Daniel Peterson, Joshua C. Pritchett, Dharam V. Ablashi, andPeter G. Medveczky; Journal of Medical Virology; published online July 25, 2013; DOI: 10.1002/jmv.23685

University of South Florida (USF Health)

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University of South Florida (USF Health). "Anti-herpesvirus drug treatment may benefit some chronic fatigue syndrome patients." Medical News Today. MediLexicon, Intl., 30 Jul. 2013. Web.
30 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Anti-herpesvirus drug treatment may benefit some chronic fatigue syndrome patients'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here